Published in Exp Hematol on November 01, 1998
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol (2007) 0.87
Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer. Chromosome Res (2006) 0.76
Studies on lysosomes. XI. Characterization of a hydrolase-rich fraction from human lymphocytes. J Cell Biol (1968) 4.22
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40
Prognosis and treatment of disseminated uveal melanoma. Cancer (1993) 1.98
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer (2012) 1.90
MspA provides the main hydrophilic pathway through the cell wall of Mycobacterium smegmatis. Mol Microbiol (2001) 1.79
Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood (1996) 1.78
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol (2002) 1.68
Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia (2004) 1.64
Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) Ann Oncol (1997) 1.63
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol (2004) 1.59
Studies on lysosomes. XII. Redistribution of acid hydrolases in human lymphocytes stimulated by phytohemagglutinin. J Cell Biol (1968) 1.58
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs (1996) 1.56
Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol (2001) 1.50
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol (1997) 1.46
Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg (1998) 1.46
Energy transfer between fluorescent proteins using a co-expression system in Mycobacterium smegmatis. Gene (2001) 1.42
Novel tumor suppressor locus in human chromosome region 3p14.2. J Natl Cancer Inst (1999) 1.42
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer (2006) 1.42
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie (2002) 1.39
D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res (2001) 1.38
Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol (1995) 1.36
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med (2007) 1.34
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia (1994) 1.32
Risk factors for venous thromboembolic events in cancer patients. Ann Oncol (2005) 1.32
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant (2003) 1.31
Template activity of nuclei from stimulated lymphocytes. Nature (1969) 1.31
Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol (1995) 1.24
Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol (1999) 1.20
In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res (1982) 1.18
Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol (1984) 1.17
Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet (1995) 1.17
Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. Ann Oncol (2007) 1.16
Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer (1995) 1.16
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 1.15
Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol (1998) 1.15
Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood (1999) 1.13
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol (2009) 1.12
Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol (1992) 1.12
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther (2002) 1.11
Letter: Decrease of T lymphocytes during ageing. Lancet (1974) 1.11
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol (2006) 1.10
Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol (1999) 1.10
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood (2001) 1.10
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol (1996) 1.09
Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res (1998) 1.09
Lymphocyte lysosomes and lysosomal enzymes in chronic lymphocytic leukemia. Blood (1973) 1.08
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol (2003) 1.07
[Chemotherapy in advanced sarcomas (author's transl)]. Dtsch Med Wochenschr (1981) 1.07
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer (2008) 1.06
Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol (1998) 1.05
Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res (2000) 1.04
Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol (2002) 1.04
Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia (1997) 1.02
Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med (1992) 1.02
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol (1999) 1.02
Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr (1987) 1.00
Why not adhere to the original Kiel classification? Lancet (1980) 1.00
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol (2005) 0.99
Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother (1996) 0.98
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology (2005) 0.98
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs (2010) 0.98
Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia (2005) 0.98
Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol (1998) 0.98
Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer (1999) 0.97
Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors. Cancer Treat Rev (1982) 0.97
Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance? Scand J Immunol (2003) 0.97
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia (2002) 0.96
Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant (2000) 0.96
Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol (1998) 0.96
Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization. Genes Chromosomes Cancer (1996) 0.96
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res (2001) 0.95
[Chemotherapy of malignant bone tumors]. Chirurg (1977) 0.95
Rosette-forming lymphocytes in Hodgkin's disease. N Engl J Med (1973) 0.95
Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant (2004) 0.95
Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant (2008) 0.94
Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer (2008) 0.94
Antigenic phenotyping of human follicular dendritic cells isolated from nonmalignant and malignant lymphatic tissue. Eur J Immunol (1990) 0.94
Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int (2000) 0.93
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Ther (2013) 0.93
Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol (1986) 0.93